Strategic Global Advisors LLC Buys 309 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Strategic Global Advisors LLC grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.8% in the fourth quarter, HoldingsChannel reports. The fund owned 3,815 shares of the company’s stock after acquiring an additional 309 shares during the period. Strategic Global Advisors LLC’s holdings in Medpace were worth $1,267,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of MEDP. R Squared Ltd bought a new position in shares of Medpace in the fourth quarter worth about $30,000. SBI Securities Co. Ltd. bought a new position in shares of Medpace in the fourth quarter worth about $31,000. Jones Financial Companies Lllp raised its stake in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after acquiring an additional 110 shares during the last quarter. Lindbrook Capital LLC raised its stake in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after acquiring an additional 29 shares during the last quarter. Finally, Assetmark Inc. raised its stake in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after acquiring an additional 29 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $305.66 on Friday. The stock has a market cap of $8.79 billion, a P/E ratio of 24.20, a P/E/G ratio of 3.81 and a beta of 1.55. The firm has a 50 day moving average price of $304.24 and a 200 day moving average price of $327.76. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million during the quarter, compared to analysts’ expectations of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter in the previous year, the company earned $3.20 earnings per share. Analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the transaction, the director now owns 2,998 shares of the company’s stock, valued at approximately $904,856.36. The trade was a 36.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 20.30% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on MEDP shares. Truist Financial lowered their price target on shares of Medpace from $333.00 to $300.00 and set a “hold” rating for the company in a research report on Wednesday, April 23rd. William Blair reiterated a “market perform” rating on shares of Medpace in a research report on Tuesday, April 22nd. Leerink Partners started coverage on shares of Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 price target for the company. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research report on Monday, March 24th. Finally, TD Cowen cut shares of Medpace from a “buy” rating to a “hold” rating and lowered their price target for the stock from $370.00 to $328.00 in a research report on Monday, April 14th. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.